Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
LoveBug Probiotics brings customers an award-winning range of probiotic supplement...
LoveBug Probiotics brings customers an award-wi...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
We are a global medical technology company focused on the design, development and ...
We are a global medical technology company focu...
resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovativ...
resTORbio, Inc. is a clinical-stage biopharmace...
vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the disc...
vTv Therapeutics is a clinical-stage biopharmac...
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.